The Content Marketing World Health Summit hosted by MedCityNews.com is one week away. On Nov. 7 and 8, attendees from across the country will converge on Cleveland for a unique experience driven by the likes of the director of Mayo Clinic’s Center for Social Media, the chief marketing and communications officer at Boston Children’s Hospital, and the senior vice president of Content Strategy & Media at Ogilvy CommonHealth Worldwide.
Two hundred people are already registered for the event. There’s only a few days left to join them by getting your tickets here.
Hospitals big and small, early stage life sciences companies, medical device marketers and cutting-edge agencies looking to get results through content have a place at this event. The subjects span from print to the most futuristic digital approaches. And it’s a truly national audience: Roughly two-thirds of conference attendees are coming from outside Ohio to take in a packed agenda.
Boston Children’s Hospital Senior Vice President Margaret Coughlin begins Day 1 with a keynote address titled: “Does Content Matter in Health Care Marketing?” Conversations also cover content strategy in pharma and include content strategy case studies for successful medical device companies.
The first day ends with a Q & A with Lee Aase, director of the Mayo Clinic Center for Social Media, outlining what he sees coming next in healthcare content. Then — after a rich day of panels, case studies, conversations and networking — attendees can choose from three workshops geared toward hospitals, business-to-business content strategy and healthcare social media.
Content has never been more important in driving healthcare business, whether it’s patient referrals, sales, fundraising or medical adherence. And every week there’s a new way to use content to help healthcare: new tools on Facebook, thought leadership features on LinkedIn, or someone finding ways to do it smarter and better.
Some see all this change as a challenge.
A Deep-dive Into Specialty Pharma
A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed “orphan” diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS.
Next week’s gathering of healthcare leaders sees the new ways as opportunities.
Join us.
[Photo courtesy of Flickr user Rennett Stowe]
